Sun Pharmaceutical reports Q2 results amid Organon acquisition charges
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Sun Pharmaceutical Industries reported a 36.2 percent year-on-year decline in consolidated net profit for the quarter ended September 2026 (Q2 FY27) due to exceptional charges related to its proposed acquisition of Organon & Co and a settlement in a US antitrust litigation case. Despite the charges, consolidated revenue from operations rose 11.9 percent year-on-year to Rs 16,198.7 crore. The company's India formulations business reported sales of Rs 5,552.3 crore, registering 17.3 percent year-on-year growth.
From moneycontrol.com
Why it matters
The proposed acquisition of Organon & Co. resulted in exceptional charges that impacted Sun Pharmaceutical Industries' net profit. However, the strong growth in the India formulations business indicates robust domestic demand for pharmaceutical products.
From moneycontrol.com
Who's involved
- Organon & Co.Pharmaceutical company that Sun Pharmaceutical Industries has proposed acquiring
- Sun PharmaceuticalIndian multinational pharmaceutical company reporting results and pursuing the acquisition of Organon & Co.